BelCaP Update on positive results for ovarian cancer presented at Biennial Ovarian Cancer Research Symposium in Seattle

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen 
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com

BelCaP Update on positive results for ovarian cancer presented at Biennial
Ovarian Cancer Research Symposium in Seattle 

Copenhagen, Denmark - September 8, 2008 - TopoTarget A/S (OMX: TOPO)  announces
that an update on positive data from the TopoTarget BelCaP combination
(Belinostat+Carboplatin+Taxol) for ovarian cancer was presented at the Biennial
Ovarian Cancer Research Symposium in Seattle 4-5 September 2008. 

”The positive data presented at this symposium is an improvement of the
positive results announced at ASCO in June. The results continue to develop
positively and now two more patients, three in total, have obtained completer
response (CR),” says Peter Buhl Jensen. ”BelCaP represents a promising approach
to a new combination therapy for patients with ovarian cancer with platinum
resistant tumours,” comments professor Peter Buhl Jensen, MD, CEO of
TopoTarget. 

The study:
Phase II open label, non-randomized multi-center trial of the Histone
Deacetylase Inhibitor belinostat, with carboplatin and paclitaxel (BelCaP) in
patients with relapsed epithelial ovarian cancer. 

35 patients were included with an overall response rate of 43%, four patients
continue on therapy.  3 complete remissions (CR) and 12 partial remissions (PR)
by RECIST criteria (Response Evaluation Criteria in Solid Tumours) have been
reported. Median time to response was 2.5 months and the median duration of
response was +5.3 months (range +1.2 to +12.7 months) with 6 responses still
ongoing. 

Conclusion:
BelCaP is well-tolerated presenting a safety profile consistent of that
observed with chemotherapy alone. Activity has been observed in patients with
platinum-sensitive and platinum-resistant tumors, including patients with a
platinum-free interval of < 3 months. The substantial anti-tumor activity
observed supports further development of BelCaP in patients with recurrent
ovarian cancer. The addition of belinostat to platinum-based regimens
represents a novel approach to therapy of ovarian cancer. Updated results will
be presented. 


Today's news does not change TopoTarget's full-year financial guidance for 2008.

TopoTarget  A/S

	
For further information, please contact:

Peter Buhl, CEO 		Telephone	+45 39 17 83 92
			Mobile	+45 21 60 89 22


Background information

About TopoTarget 
TopoTarget (OMX: TOPO) is an international biotech company headquartered in
Denmark, dedicated to finding ''Answers for Cancer'' and developing improved
cancer therapies. The company is founded and run by clinical cancer specialists
and combines years of hands-on clinical experience with in-depth understanding
of the molecular mechanisms of cancer. Focus lies on highly predictive cancer
models and key cancer targets (including HDACi, NAD+, mTOR, FasLigand and
topoisomerase II inhibitors). TopoTarget has a broad cllinical pipeline with 9
products in development, including belinostat which has shown proof of concept
as monotherapy in treating haematological malignancies and positive results in
solid tumours where it can be used in combination with full doses of
chemotherapy. The company's first marketed product Savene®/Totect® was approved
by EMEA in 2006 and the FDA in 2007 and is marketed by TopoTarget's own sales
force in Europe and the US. For more information, please refer to
www.topotarget.com. 

TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. TopoTarget cautions investors that
there can be no assurance that actual results or business conditions will not
differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
TopoTarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks;  uncertainty of additional funding; TopoTarget's history of
incurring losses and the uncertainty of achieving profitability; TopoTarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against TopoTarget's products, processes and
technologies; the ability to protect TopoTarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability expo-sure; We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.